IPCA Laboratories Q2 Results 2025 Highlights: Net Profit Rises by 23.13% & Revenue Up 8.56% YoY

IPCA Laboratories Q2 Results FY26: During Q2 FY26, IPCA Laboratories’ profit increased 23.13% YoY, while revenue increased by 8.56% YoY. The company posted robust numbers, with Q2 PAT at ₹282.57 crores and revenue at ₹2,556.50 crores. IPCA Laboratories announced its Q2 results on 13th November 2025.  

IPCA Laboratories Q2 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

IPCA Laboratories Q2 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

IPCA Laboratories Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• IPCA Laboratories clocked Q2 FY26 consolidated revenue of ₹2,556.50 crores vs ₹2,354.90 crores. 
• On the profit front, IPCA Laboratories earned a consolidated PAT of ₹282.57 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹229.48 crore.
• According to the consolidated figures, IPCA Laboratories’ quarterly PAT increased by 23.13% YoY, while revenue increased by 8.56%.
• IPCA Laboratories clocked Q2 FY26 standalone revenue of ₹1,930.32 crores vs ₹1,810.94 crores. 
• On the profit front, IPCA Laboratories earned a standalone PAT of ₹304.74 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹244.12 crore.
• According to the standalone figures, IPCA Laboratories’ quarterly PAT increased by 24.83% YoY, while revenue increased by 6.59%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

IPCA Laboratories Share Price Performance

On the opening bell on 19th November 2025, IPCA Laboratories shares opened at ₹1,432.90 per share. However, the initial gains have since eroded, and IPCA Laboratories shares are currently trading at ₹1,425.90 per share, below the opening price.    

Considering the long-term achievements, IPCA Laboratories shares have yielded returns of approximately -9.44% over the past years, and 5-year returns stand at 33.34%. Over the maximum timeframe, IPCA Laboratories shares delivered a 28,706.06% return to investors. 

What Analysts Expect Post Q2 Results?

Following IPCA Laboratories’ robust Q2 results, analysts expect its share price to rise. According to analysts, IPCA Laboratories’ price is expected to reach ₹1,510.30 per share in the coming year; however, in a downturn, it could fall to ₹1,405.80 per share. However, one must ignore stock market volatility and invest in IPCA Laboratories’ shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here